(Q36544924)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16863444%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

review article

1 reference

title

Toxic metabolic syndrome associated with HAART (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16863444%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

Steen Bendix Haugaard

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16863444%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Steen B Haugaard

series ordinal

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16863444%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

27 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16863444%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16863444%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16863444%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

429-445

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16863444%20AND%20SRC:MED&resulttype=core&format=json

"Buffalo hump" in men with HIV-1 infection.

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Indinavir-associated lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

An objective case definition of lipodystrophy in HIV-infected adults: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Fat distribution in men with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

HIV protease inhibitors stimulate hepatic triglyceride synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

In vivo evidence of impaired peripheral fatty acid trapping in patients with human immunodeficiency virus-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Metabolic basis of HIV-lipodystrophy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Apo CIII gene transcription is regulated by a cytokine inducible NF-kappa B element

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

HDL metabolism in hypertriglyceridemic states: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Impact of HIV infection and HAART on serum lipids in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodeficiency virus type 1-infected T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Promoter analysis of the mouse sterol regulatory element-binding protein-1c gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Adiponectin: action, regulation and association to insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

The current biology of resistin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Factors Associated With Mitochondrial Dysfunction in Circulating Peripheral Blood Lymphocytes From HIV-Infected People

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Kinetics of lactate metabolism after submaximal ergometric exercise in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Preanalytical handling of samples for measurement of plasma lactate in HIV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

The effect of long-term storage on measured plasma lactate concentrations and prospective lactate results from a multicenter trial of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Diabetes, insulin resistance, and dementia among HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

The metabolic effects of lopinavir/ritonavir in HIV-negative men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Metabolic effects of indinavir in healthy HIV-seronegative men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Skeletal muscle insulin signaling defects downstream of phosphatidylinositol 3-kinase at the level of Akt are associated with impaired nonoxidative glucose disposal in HIV lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

In nondiabetic, human immunodeficiency virus-infected patients with lipodystrophy, hepatic insulin extraction and posthepatic insulin clearance rate are decreased in proportion to insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Insulin stimulates interleukin-6 and tumor necrosis factor-alpha gene expression in human subcutaneous adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Low plasma levels of dehydroepiandrosterone (DHEA) and incidence of lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Peroxisomal proliferator-activated ligand therapy for HIV lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Vitamin D and calcium deficits predispose for multiple chronic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Association between AIDS disease progression rates and the Fok-I polymorphism of the VDR gene in a cohort of HIV-1 seropositive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Selective parasympathetic innervation of subcutaneous and intra-abdominal fat--functional implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Sonographic assessment of regional fat in HIV-1-infected people

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Fat distribution and metabolic changes in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Coronary heart disease in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Brucella prostatic abscess: first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

Demonstration of estrogen receptor subtypes alpha and beta in human adipose tissue: influences of adipose cell differentiation and fat depot localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.3.429

21 January 2018

Identifiers

DOI

10.1517/17425255.2.3.429

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16863444%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference